BR112019001206A2 - anticorpos monoclonais humanizados que visam ve-ptp (hptp-ss) - Google Patents
anticorpos monoclonais humanizados que visam ve-ptp (hptp-ss)Info
- Publication number
- BR112019001206A2 BR112019001206A2 BR112019001206A BR112019001206A BR112019001206A2 BR 112019001206 A2 BR112019001206 A2 BR 112019001206A2 BR 112019001206 A BR112019001206 A BR 112019001206A BR 112019001206 A BR112019001206 A BR 112019001206A BR 112019001206 A2 BR112019001206 A2 BR 112019001206A2
- Authority
- BR
- Brazil
- Prior art keywords
- hptp
- ptp
- monoclonal antibodies
- humanized monoclonal
- antibodies targeting
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
a revelação proporciona composições e métodos para o tratamento de condições oculares associadas a angiogênese compreendendo a administração de um anticorpo que visa um inibidor da tirosina fosfatase num indivíduo.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662364381P | 2016-07-20 | 2016-07-20 | |
US201662377072P | 2016-08-19 | 2016-08-19 | |
PCT/US2017/042855 WO2018017714A1 (en) | 2016-07-20 | 2017-07-19 | HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-ß) |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112019001206A2 true BR112019001206A2 (pt) | 2019-06-25 |
Family
ID=60988231
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112019001206A BR112019001206A2 (pt) | 2016-07-20 | 2017-07-19 | anticorpos monoclonais humanizados que visam ve-ptp (hptp-ss) |
Country Status (13)
Country | Link |
---|---|
US (6) | US10253094B2 (pt) |
EP (1) | EP3487518A4 (pt) |
JP (3) | JP7107914B2 (pt) |
KR (1) | KR20190031246A (pt) |
CN (1) | CN109715189A (pt) |
AU (1) | AU2017299581B2 (pt) |
BR (1) | BR112019001206A2 (pt) |
CA (1) | CA3030298A1 (pt) |
IL (1) | IL263936A (pt) |
MX (1) | MX2019000727A (pt) |
PH (1) | PH12019500145A1 (pt) |
SG (2) | SG11201900464TA (pt) |
WO (1) | WO2018017714A1 (pt) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0710645A2 (pt) | 2006-04-07 | 2012-03-20 | The Procter & Gamble Company | Anticorpos que se ligam à proteína humana tirosina fosfatase beta (hptpbeta) e usos dos mesmos |
US7622593B2 (en) | 2006-06-27 | 2009-11-24 | The Procter & Gamble Company | Human protein tyrosine phosphatase inhibitors and methods of use |
EP3501536A1 (en) * | 2011-10-13 | 2019-06-26 | Aerpio Therapeutics, Inc. | Treatment of ocular disease |
CN104039351A (zh) | 2011-10-13 | 2014-09-10 | 阿尔皮奥治疗学股份有限公司 | 用于治疗血管渗漏综合征和癌症的方法 |
MX2018015755A (es) | 2016-06-15 | 2019-08-29 | Icahn School Med Mount Sinai | Proteinas de hemaglutinina de virus de influenza y usos de las mismas. |
US10253094B2 (en) | 2016-07-20 | 2019-04-09 | Aerpio Therapeutics, Inc. | Antibodies that target human protein tyrosine phosphatase-beta (HPTP-beta) and methods of use thereof to treat ocular conditions |
CA3058652A1 (en) | 2017-04-07 | 2018-10-11 | Icahn School Of Medicine At Mount Sinai | Anti-influenza b virus neuraminidase antibodies and uses thereof |
CN113164597A (zh) * | 2018-09-24 | 2021-07-23 | 爱尔皮奥制药公司 | 靶向HPTP-β(VE-PTP)和VEGF的多特异性抗体 |
WO2020117373A1 (en) * | 2018-12-03 | 2020-06-11 | Agensys, Inc. | Pharmaceutical compositions comprising anti-191p4d12 antibody drug conjugates and methods of use thereof |
CA3137160A1 (en) * | 2019-04-24 | 2020-10-29 | Icahn School Of Medicine At Mount Sinai | Anti-influenza b virus neuraminidase antibodies and uses thereof |
GB2589400A (en) | 2019-06-24 | 2021-06-02 | Aerpio Pharmaceuticals Inc | Formulations of tie-2 activators and methods of use thereof |
Family Cites Families (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI1325932T1 (pt) | 1997-04-07 | 2005-08-31 | Genentech Inc | |
US6455035B1 (en) | 1999-03-26 | 2002-09-24 | Regeneron Pharmaceuticals, Inc. | Angiopoietins and methods of use thereof |
DK1165115T3 (da) | 1999-03-26 | 2003-09-22 | Regeneron Pharma | Modulering af vaskulær permeabilitet ved hjælp af TIE2-receptor aktivatorer |
EP1046715A1 (en) | 1999-04-23 | 2000-10-25 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Interaction of vascular-endothelial protein-tyrosine phosphatase with the angiopoietin receptor tie-2 |
US20020068066A1 (en) * | 1999-08-20 | 2002-06-06 | Wenyuan Shi | Method for the treatment and prevention of dental caries |
DE60128685T2 (de) | 2000-06-23 | 2009-03-05 | Bayer Schering Pharma Aktiengesellschaft | Zusammensetzungen, die mit vegf/vegf und angiopoietin/tie rezeptor-funktionen interferieren |
KR20040039428A (ko) | 2001-09-28 | 2004-05-10 | 산텐 세이야꾸 가부시키가이샤 | 약물-폴리에틸렌글리콜 결합체를 함유하는 안조직 내 주입제 |
US20050260132A1 (en) | 2001-10-17 | 2005-11-24 | Daniel Chin | Monoclonal antibodies directed to receptor protein tyrosine phosphatase zeta |
JP2005511660A (ja) | 2001-12-04 | 2005-04-28 | デヴェロゲン アクチエンゲゼルシャフト フュア エントヴィックルングスビオローギッシェ フォルシュング | エネルギー恒常性の調節に関与する、PTP10D、Tecタンパク質チロシンキナーゼおよびEDTPの相同性タンパク質 |
US20030215899A1 (en) | 2002-02-13 | 2003-11-20 | Ceptyr, Inc. | Reversible oxidation of protein tyrosine phosphatases |
US20040023880A1 (en) | 2002-05-03 | 2004-02-05 | Gale Nicholas W. | Methods of inducing formation of functional and organized lymphatic vessels |
US7507568B2 (en) | 2002-09-25 | 2009-03-24 | The Proctor & Gamble Company | Three dimensional coordinates of HPTPbeta |
US7226755B1 (en) | 2002-09-25 | 2007-06-05 | The Procter & Gamble Company | HPTPbeta as a target in treatment of angiogenesis mediated disorders |
JP2008531557A (ja) | 2005-02-23 | 2008-08-14 | メリマック ファーマシューティカルズ インコーポレーティッド | 生物活性を調節するための二重特異性結合剤 |
WO2007033216A2 (en) | 2005-09-12 | 2007-03-22 | Beth Israel Deaconess Medical Center | Methods and compositions for the treatment and diagnosis of diseases characterized by vascular leak, hypotension, or a procoagulant state |
JP2009510102A (ja) | 2005-09-29 | 2009-03-12 | ヴァイラル ロジック システムズ テクノロジー コーポレーション | 免疫調節組成物およびその使用 |
BRPI0619853A2 (pt) | 2005-12-15 | 2016-08-23 | Astrazeneca Ab | combinação, composição farmacêutica, e, métodos de antagonização da atividade biológica, de tratamento de angiogênese relacionada à doença em um mamífero e de tratamento de câncer em um mamífero |
WO2007087457A2 (en) | 2006-01-30 | 2007-08-02 | (Osi) Eyetech, Inc. | Combination therapy for the treatment of neovascular disorders |
EP3539989A1 (en) | 2006-03-10 | 2019-09-18 | Wyeth LLC | Anti-5t4 antibodies and uses thereof |
CA2647282A1 (en) | 2006-04-05 | 2007-10-11 | Pfizer Products Inc. | Ctla4 antibody combination therapy |
BRPI0710645A2 (pt) | 2006-04-07 | 2012-03-20 | The Procter & Gamble Company | Anticorpos que se ligam à proteína humana tirosina fosfatase beta (hptpbeta) e usos dos mesmos |
US20130023542A1 (en) | 2006-06-27 | 2013-01-24 | Aerpio Therapeutics Inc. | Human protein tyrosine phosphatase inhibitors and methods of use |
US7589212B2 (en) | 2006-06-27 | 2009-09-15 | Procter & Gamble Company | Human protein tyrosine phosphatase inhibitors and methods of use |
US7622593B2 (en) | 2006-06-27 | 2009-11-24 | The Procter & Gamble Company | Human protein tyrosine phosphatase inhibitors and methods of use |
US7795444B2 (en) | 2006-06-27 | 2010-09-14 | Warner Chilcott Company | Human protein tyrosine phosphatase inhibitors and methods of use |
US8846685B2 (en) | 2006-06-27 | 2014-09-30 | Aerpio Therapeutics Inc. | Human protein tyrosine phosphatase inhibitors and methods of use |
US8642067B2 (en) | 2007-04-02 | 2014-02-04 | Allergen, Inc. | Methods and compositions for intraocular administration to treat ocular conditions |
AU2008268262C1 (en) | 2007-06-26 | 2015-02-19 | Children's Medical Center Corporation | MetAP-2 inhibitor polymersomes for therapeutic administration |
US20100260668A1 (en) * | 2008-04-29 | 2010-10-14 | Abbott Laboratories | Dual Variable Domain Immunoglobulins and Uses Thereof |
WO2009154026A1 (ja) | 2008-06-20 | 2009-12-23 | 国立大学法人岡山大学 | 石灰化小球に対する抗体及びその用途 |
US8901076B2 (en) | 2008-11-03 | 2014-12-02 | Molecular Partner AG | Binding proteins inhibiting the VEGF-A receptor interaction |
RU2014146121A (ru) | 2009-01-12 | 2015-06-10 | Аэрпио Терапьютикс Инк. | Способы лечения синдрома сосудистой утечки |
US9096555B2 (en) | 2009-01-12 | 2015-08-04 | Aerpio Therapeutics, Inc. | Methods for treating vascular leak syndrome |
WO2010097800A1 (en) | 2009-02-26 | 2010-09-02 | Muhammad Abdulrazik | Synergistic combination of bioactive compounds for lowering of intraocular pressure |
CN102428103B (zh) * | 2009-03-24 | 2015-04-08 | 泰华生物制药美国公司 | 抗light的人源化抗体及其使用 |
ES2726946T3 (es) | 2009-07-06 | 2019-10-10 | Aerpio Therapeutics Inc | Derivados de benzosulfonamida, composiciones de los mismos y su uso en la prevención de la metástasis de las células cancerosas |
US8883832B2 (en) | 2009-07-06 | 2014-11-11 | Aerpio Therapeutics Inc. | Compounds, compositions, and methods for preventing metastasis of cancer cells |
BR112012012887A2 (pt) * | 2009-12-02 | 2017-05-02 | Imaginab Inc | minicorpo e cys-diabody (cysdb) codificados por sequência de nucleótidos, respectivo uso e métodos de diagnósticos e de tratamento de câncer associado com a expressão de psma num sujeito. |
TWI510246B (zh) | 2010-04-30 | 2015-12-01 | Molecular Partners Ag | 抑制vegf-a受體交互作用的經修飾結合性蛋白質 |
JP2013539756A (ja) | 2010-10-07 | 2013-10-28 | アエルピオ セラピューティックス インコーポレイテッド | 眼球浮腫、血管新生および関連疾患を処置するための組成物および方法 |
US20180092883A1 (en) | 2010-10-07 | 2018-04-05 | Aerpio Therapeutics, Inc. | Phosphatase inhibitors for treating ocular diseases |
CA2827082A1 (en) | 2011-02-11 | 2012-08-16 | Psivida Us, Inc. | Methods of treating macular edema using antiedema therapeutics |
JP6400470B2 (ja) * | 2011-05-16 | 2018-10-03 | ジェネロン(シャンハイ)コーポレイション リミテッド | 多重特異性Fab融合タンパク質および使用法 |
EP3501536A1 (en) | 2011-10-13 | 2019-06-26 | Aerpio Therapeutics, Inc. | Treatment of ocular disease |
CN104039351A (zh) | 2011-10-13 | 2014-09-10 | 阿尔皮奥治疗学股份有限公司 | 用于治疗血管渗漏综合征和癌症的方法 |
WO2014009465A1 (en) | 2012-07-13 | 2014-01-16 | Roche Glycart Ag | Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases |
US20150258120A1 (en) | 2012-11-08 | 2015-09-17 | Clearside Biomedical, Inc. | Methods and devices for the treatment of ocular diseases in human subjects |
US20150050277A1 (en) | 2013-03-15 | 2015-02-19 | Aerpio Therapeutics Inc. | Compositions and methods for treating ocular diseases |
ES2766326T3 (es) | 2013-03-15 | 2020-06-12 | Aerpio Therapeutics Inc | Composiciones, formulaciones y métodos para tratar enfermedades oculares |
US20160130321A1 (en) | 2013-06-20 | 2016-05-12 | Gabriela Burian | Use of a vegf antagonist in treating macular edema |
EP3010525A1 (en) | 2013-06-20 | 2016-04-27 | Novartis AG | Use of a vegf antagonist in treating choroidal neovascularisation |
CA2917813A1 (en) | 2013-07-11 | 2015-01-15 | Novartis Ag | Use of a vegf antagonist in treating retinopathy of prematurity |
CA2917807A1 (en) | 2013-07-11 | 2015-01-15 | Novartis Ag | Use of a vegf antagonist in treating chorioretinal neovascular and permeability disorders in paediatric patients |
US10617755B2 (en) | 2013-08-30 | 2020-04-14 | Genentech, Inc. | Combination therapy for the treatment of glioblastoma |
CN105636986B (zh) | 2013-10-18 | 2020-05-12 | 瑞泽恩制药公司 | 包含vegf拮抗剂和抗-ctla-4抗体的组合的方法和组合物 |
SG10201805934RA (en) | 2014-01-10 | 2018-08-30 | Anaptysbio Inc | Antibodies directed against interleukin-33 (il-33) |
WO2015138882A1 (en) | 2014-03-14 | 2015-09-17 | Aerpio Therapeutics, Inc. | Hptp-beta inhibitors |
US9719135B2 (en) | 2014-07-03 | 2017-08-01 | Mannin Research Inc. | Conditional angiopoietin-1/angiopoietin-2 double knock-out mice with defective ocular drainage system |
US9539245B2 (en) | 2014-08-07 | 2017-01-10 | Aerpio Therapeutics, Inc. | Combination of immunotherapies with activators of Tie-2 |
EA201790236A1 (ru) | 2014-09-16 | 2017-11-30 | Оувэсайенс, Инк. | Антитела против vasa и способы их получения и использования |
WO2016049183A1 (en) | 2014-09-24 | 2016-03-31 | Aerpio Therapeutics, Inc. | Ve-ptp extracellular domain antibodies delivered by a gene therapy vector |
TWI761959B (zh) | 2014-11-07 | 2022-04-21 | 瑞士商諾華公司 | 治療眼部疾病之方法 |
US20160144025A1 (en) | 2014-11-25 | 2016-05-26 | Regeneron Pharmaceuticals, Inc. | Methods and formulations for treating vascular eye diseases |
CN107454904A (zh) | 2015-04-02 | 2017-12-08 | 分子组合公司 | 对血清白蛋白具有结合特异性的经设计的锚蛋白重复结构域 |
US11091559B2 (en) | 2015-08-27 | 2021-08-17 | Celldex Therapeutics, Inc. | Anti-ALK antibodies and methods for use thereof |
JP6959924B2 (ja) | 2015-09-23 | 2021-11-05 | エアーピオ ファーマシューティカルズ, インコーポレイテッド | Tie−2の活性化物質を用いる眼内圧を処置する方法 |
CA2992602A1 (en) | 2015-09-23 | 2017-03-30 | Genentech, Inc. | Optimized variants of anti-vegf antibodies |
CN109069638B (zh) | 2016-03-24 | 2022-03-29 | 璟尚生物制药公司 | 用于癌症治疗的三特异性抑制剂 |
US10253094B2 (en) | 2016-07-20 | 2019-04-09 | Aerpio Therapeutics, Inc. | Antibodies that target human protein tyrosine phosphatase-beta (HPTP-beta) and methods of use thereof to treat ocular conditions |
-
2017
- 2017-07-19 US US15/654,289 patent/US10253094B2/en active Active
- 2017-07-19 EP EP17831790.5A patent/EP3487518A4/en active Pending
- 2017-07-19 CA CA3030298A patent/CA3030298A1/en active Pending
- 2017-07-19 AU AU2017299581A patent/AU2017299581B2/en active Active
- 2017-07-19 WO PCT/US2017/042855 patent/WO2018017714A1/en unknown
- 2017-07-19 BR BR112019001206A patent/BR112019001206A2/pt not_active Application Discontinuation
- 2017-07-19 KR KR1020197002479A patent/KR20190031246A/ko not_active Application Discontinuation
- 2017-07-19 SG SG11201900464TA patent/SG11201900464TA/en unknown
- 2017-07-19 JP JP2019502696A patent/JP7107914B2/ja active Active
- 2017-07-19 CN CN201780057896.9A patent/CN109715189A/zh active Pending
- 2017-07-19 SG SG10201912556VA patent/SG10201912556VA/en unknown
- 2017-07-19 MX MX2019000727A patent/MX2019000727A/es unknown
-
2018
- 2018-11-05 US US16/180,850 patent/US10604569B2/en active Active
- 2018-11-05 US US16/180,854 patent/US10597452B2/en active Active
- 2018-12-24 IL IL263936A patent/IL263936A/en unknown
-
2019
- 2019-01-18 PH PH12019500145A patent/PH12019500145A1/en unknown
-
2020
- 2020-01-29 US US16/775,860 patent/US11136389B2/en active Active
- 2020-04-17 US US16/851,420 patent/US11180551B2/en active Active
- 2020-07-14 JP JP2020120521A patent/JP2020180156A/ja active Pending
-
2022
- 2022-05-02 JP JP2022075926A patent/JP2022101694A/ja active Pending
- 2022-05-27 US US17/804,396 patent/US20230134885A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2018017714A1 (en) | 2018-01-25 |
US10253094B2 (en) | 2019-04-09 |
US11180551B2 (en) | 2021-11-23 |
US10597452B2 (en) | 2020-03-24 |
AU2017299581A1 (en) | 2019-01-17 |
EP3487518A4 (en) | 2020-08-12 |
SG10201912556VA (en) | 2020-02-27 |
EP3487518A1 (en) | 2019-05-29 |
JP2020180156A (ja) | 2020-11-05 |
SG11201900464TA (en) | 2019-02-27 |
CA3030298A1 (en) | 2018-01-25 |
US20200270342A1 (en) | 2020-08-27 |
JP2019531259A (ja) | 2019-10-31 |
US11136389B2 (en) | 2021-10-05 |
US10604569B2 (en) | 2020-03-31 |
US20180022804A1 (en) | 2018-01-25 |
KR20190031246A (ko) | 2019-03-25 |
CN109715189A (zh) | 2019-05-03 |
US20200239567A1 (en) | 2020-07-30 |
MX2019000727A (es) | 2019-05-02 |
US20190077862A1 (en) | 2019-03-14 |
PH12019500145A1 (en) | 2019-07-29 |
JP2022101694A (ja) | 2022-07-06 |
US20190077863A1 (en) | 2019-03-14 |
JP7107914B2 (ja) | 2022-07-27 |
IL263936A (en) | 2019-01-31 |
US20230134885A1 (en) | 2023-05-04 |
AU2017299581B2 (en) | 2024-05-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112019001206A2 (pt) | anticorpos monoclonais humanizados que visam ve-ptp (hptp-ss) | |
CL2017003195A1 (es) | Anticuerpos madurados por afinidad y humanizados para fcrh5 y métodos para su uso. | |
CO2017013356A2 (es) | Anticuerpos de factor xi | |
CL2019003657A1 (es) | Anticuerpos que se unen específicamente a cd38 útiles para mejorar una respuesta inmune en un paciente. (divisional solicitud 201703275) | |
CL2019003093A1 (es) | Anticuerpos anti-trem2 y métodos para utilizarlos. | |
BR112018014016A2 (pt) | combinação de um agonista de ox40 e um agonista de anticorpo monoclonal 4-1bb para tratamento de câncer | |
BR112018070919A2 (pt) | anticorpos anti-tim-3 e composições | |
CO2017010618A2 (es) | Anticuerpos contra icos | |
BR112016014952A2 (pt) | Inibição direcionada de tgfbeta | |
BR112017028353A2 (pt) | anticorpos para cd40 com atividade agonista melhorada | |
CO2018011195A2 (es) | Composiciones que comprenden una coformulación de anticuerpos anti-pd-l1 y anti-ctla-4 | |
CO2019012143A2 (es) | Formulaciones estables de anticuerpos anti-ctla4 solos y en combinación con anticuerpos contra el receptor de muerte programada 1 (pd-1) y métodos para su uso | |
BR112018012929A2 (pt) | anticorpos anti-cd20/anti-cd3 biespecíficos para tratar leucemia linfoblástica aguda | |
CL2019000508A1 (es) | Formulaciones, kits y métodos de anticuerpos inhibidores de masp-2 de baja viscosidad altamente concentrados. | |
CR20190105A (es) | Composiciones y métodos de inhibir masp-3 para el tratamiento de diversas enfermedades y trastornos | |
BR112019002331A2 (pt) | anticorpos anti-siglec-7 para o tratamento do câncer e métodos para obtenção dos mesmos | |
BR112018070948A2 (pt) | anticorpos anti-psma e utilização dos mesmos | |
BR112016014731A2 (pt) | Anticorpos anti-baff | |
CO2018005393A2 (es) | Anticuerpos anti-htra1 y métodos de uso de los mismos | |
EP4234013A3 (en) | Methods for treating or preventing atherosclerosis by administering an inhibitor of angptl3 | |
EA201992248A1 (ru) | АНТИ-C5a-АНТИТЕЛА И ИХ ПРИМЕНЕНИЯ | |
EA201992027A1 (ru) | Водный состав антитела против pd-l1 | |
BR112017002433A2 (pt) | anticorpos anticeramida | |
UY37598A (es) | Anticuerpos miméticos de fgf21 y usos de los mismos | |
EA201891527A1 (ru) | Композиции и способы обнаружения и лечения рака пищевода |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] |